Pathogenesis, clinical and laboratory aspects of thrombosis in cancer

[1]  K. Ekdahl,et al.  Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. , 2007, Seminars in thrombosis and hemostasis.

[2]  K. Aonuma,et al.  Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer , 2007, British Journal of Cancer.

[3]  U. Pendurthi,et al.  Microvesicle‐associated tissue factor and Trousseau's syndrome , 2007, Journal of thrombosis and haemostasis : JTH.

[4]  U. Rauch,et al.  Tissue factor-positive microparticles in blood associated with coagulopathy in cancer , 2006, Thrombosis and Haemostasis.

[5]  M. Suckow,et al.  Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund–Wistar rats , 2007, Cancer Immunology, Immunotherapy.

[6]  J. Rak,et al.  Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. , 2006, Cancer research.

[7]  S. Karpatkin,et al.  Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. , 2006, Cancer cell.

[8]  P. Rose,et al.  High D‐dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes , 2006, British journal of haematology.

[9]  Xiaofeng Jiang,et al.  Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells , 2006, Thrombosis and Haemostasis.

[10]  N. Barbarroja,et al.  Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies , 2006, Leukemia.

[11]  D. Goodsell.  The molecular perspective: tissue factor. , 2006, The oncologist.

[12]  H. Rousset,et al.  Maladie veineuse thromboembolique et cancer , 2006 .

[13]  G. Agnelli,et al.  Therapy Insight: venous-catheter-related thrombosis in cancer patients , 2006, Nature Clinical Practice Oncology.

[14]  N. Mackman.  Role of tissue factor in hemostasis and thrombosis. , 2006, Blood cells, molecules & diseases.

[15]  A. Chu.  Tissue factor upregulation drives a thrombosis–inflammation circuit in relation to cardiovascular complications , 2006, Cell biochemistry and function.

[16]  R. Saxena,et al.  Roles of protein C, protein S, and antithrombin III in acute leukemia , 2006, American journal of hematology.

[17]  J. Rak,et al.  Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. , 2006, Vnitrni lekarstvi.

[18]  J. Rak,et al.  Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. , 2006, Seminars in thrombosis and hemostasis.

[19]  W. Ruf,et al.  Thrombin generation and the pathogenesis of cancer. , 2006, Seminars in thrombosis and hemostasis.

[20]  J. Heit.  The Epidemiology of Venous Thromboembolism in the Community: Implications for Prevention and Management , 2006, Journal of Thrombosis and Thrombolysis.

[21]  P. Prandoni,et al.  Cancer and venous thromboembolism. , 1996, Seminars in thrombosis and hemostasis.

[22]  Tufia C Haddad,et al.  Chemotherapy-induced thrombosis. , 2006, Thrombosis research.

[23]  M. Yano,et al.  Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. , 2006, Journal of the American College of Surgeons.

[24]  Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. , 2005, Cancer letters.

[25]  A. Falanga.  Thrombophilia in cancer. , 2005, Seminars in thrombosis and hemostasis.

[26]  S. Mousa.  Antithrombotics in thrombosis and cancer , 2003, Hamostaseologie.

[27]  M. Prins,et al.  Once versus twice daily LMWH for the initial treatment of venous thromboembolism. , 2002, The Cochrane database of systematic reviews.

[28]  R. Schutgens,et al.  The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. , 2005, Haematologica.

[29]  F. Turturro,et al.  Plasma Coagulation Markers in Patients with Solid Tumors and Venous Thromboembolic Disease Receiving Oral Anticoagulation Therapy , 2004, Clinical Cancer Research.

[30]  B. Østerud,et al.  Tissue factor: (patho)physiology and cellular biology , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[31]  M. Dewhirst,et al.  Circulating D‐dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma , 2004, Cancer.

[32]  M. Prins,et al.  Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial , 2004, Journal of thrombosis and haemostasis : JTH.

[33]  M. Prins,et al.  Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism , 2004, Journal of thrombosis and haemostasis : JTH.

[34]  Sue Jones,et al.  In proven deep vein thrombosis, a low positive D-Dimer score is a strong negative predictor for associated malignancy , 2004, Thrombosis and Haemostasis.

[35]  James J. P. Stewart,et al.  Comparison of the accuracy of semiempirical and some DFT methods for predicting heats of formation , 2004, Journal of molecular modeling.

[36]  A. Yılmaz,et al.  Prognostic significance of hemostatic parameters in patients with lung cancer. , 2004, Respiratory medicine.

[37]  H. K. Kim,et al.  Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[38]  José A López,et al.  Deep venous thrombosis. , 2004, Hematology. American Society of Hematology. Education Program.

[39]  M. De Cicco.  The prothrombotic state in cancer: pathogenic mechanisms. , 2004, Critical reviews in oncology/hematology.

[40]  P. Salama.  [Thrombosis and cancer]. , 2004, Anales del sistema sanitario de Navarra.

[41]  H. Versteeg.  Tissue factor as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction. , 2004, Seminars in hematology.

[42]  D. Richel,et al.  Tissue Factor and Cancer Metastasis: The Role of Intracellular and Extracellular Signaling Pathways , 2004, Molecular medicine.

[43]  G. Lip,et al.  Virchow’s Triad Revisited: Blood Constituents , 2003, Pathophysiology of Haemostasis and Thrombosis.

[44]  A. Falanga,et al.  Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. , 2003, Clinical advances in hematology & oncology : H&O.

[45]  C. Hack,et al.  Pro‐ and non‐coagulant forms of non‐cell‐bound tissue factor in vivo , 2003, Journal of thrombosis and haemostasis : JTH.

[46]  M. Levine,et al.  Risk Assessment and Primary VTE Prevention in the Cancer Patient , 2003, Pathophysiology of Haemostasis and Thrombosis.

[47]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[48]  S. Parmar,et al.  Pathogenesis of increased risk of thrombosis in cancer. , 2003, Seminars in thrombosis and hemostasis.

[49]  Y. Nemerson,et al.  Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein , 2003, Nature Medicine.

[50]  M. Levine,et al.  Thrombotic disorders: diagnosis and treatment. , 2003, Hematology. American Society of Hematology. Education Program.

[51]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[52]  M. Fey,et al.  Coagulation Markers Predict Survival in Cancer Patients , 2002, Thrombosis and Haemostasis.

[53]  T. Panzarella,et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. , 2002, Blood.

[54]  Agnes Y. Y. Lee.  Cancer and thromboembolic disease: pathogenic mechanisms. , 2002, Cancer treatment reviews.

[55]  S. Mousa.  Anticoagulants in thrombosis and cancer: the missing link , 2002, Expert review of anticancer therapy.

[56]  T. Robak,et al.  The Influence of Low Molecular Weight Heparin on the Intravascular Activation of the Coagulation System in Patients With Acute Leukemia During Induction Chemotherapy--Report of a Prospective Randomized Study , 2002, Leukemia & lymphoma.

[57]  M T Sampson,et al.  Coagulation proteases and human cancer. , 2001, Biochemical Society transactions.

[58]  U. Pendurthi,et al.  Factor VIIa/tissue factor-induced signaling: a link between clotting and disease. , 2002, Vitamins and hormones.

[59]  Yves Gruel,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of internal medicine.

[60]  J. Navarro,et al.  Coagulative system activation and fibrinolytic system inhibition activities arise from tumoral draining vein in colon carcinoma. , 2001, Thrombosis research.

[61]  M. Samama,et al.  The Thrombophilic State in Cancer Patients , 2001, Acta Haematologica.

[62]  S. Gordon,et al.  Update on Tumor Cell Procoagulant Factors , 2001, Acta Haematologica.

[63]  S. Laporte,et al.  Meta‐analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery , 2001, The British journal of surgery.

[64]  W Ruf,et al.  Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. , 2001, Blood.

[65]  C. V. van Noorden,et al.  The complex effects of heparins on cancer progression and metastasis in experimental studies. , 2001, Pharmacological reviews.

[66]  S. Zahler,et al.  Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. , 2001, Biochemical and biophysical research communications.

[67]  G. D. Hunter,et al.  Proteinase-activated receptors. , 2001, Pharmacological reviews.

[68]  J. Olsen,et al.  Prognosis of cancers associated with venous thromboembolism. , 2000, The New England journal of medicine.

[69]  J. Herbert,et al.  Factor Xa Activates Endothelial Cells by a Receptor Cascade Between EPR-1 and PAR-2 , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[70]  O. Hoffmann,et al.  Perioperative development of a thrombogenic risk profile in patients with carcinomas of the breast: a cause of increased thrombosis. , 2000, European journal of gynaecological oncology.

[71]  V. Anisimov,et al.  Microvascular endothelium dysfunction during growth of transplanted lymphosarcoma and glioma in rats. , 1999, Journal of experimental & clinical cancer research : CR.

[72]  T. Hastie,et al.  Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis , 1999, Annals of Internal Medicine.

[73]  M. Gould,et al.  Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. , 1999, Annals of internal medicine.

[74]  A. Falanga,et al.  Pathophysiology of the Thrombophilic State in the Cancer Patient , 1999, Seminars in thrombosis and hemostasis.

[75]  B. Binder,et al.  [Pathophysiology of immobilization]. , 1999, Wiener medizinische Wochenschrift.

[76]  R J Hettiarachchi,et al.  Undiagnosed malignancy in patients with deep vein thrombosis , 1998, Cancer.

[77]  J. Olsen,et al.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. , 1998, The New England journal of medicine.

[78]  J. Hirsh,et al.  The Occurrence of Subsequent Malignancy in Patients Presenting with Deep Vein Thrombosis: Results from a Historical Cohort Study , 1998, Thrombosis and Haemostasis.

[79]  J. Emmerich,et al.  Occult cancer in patients with bilateral deep-vein thrombosis , 1997, The Lancet.

[80]  M. Monreal,et al.  Occult Cancer in Patients with Venous Thromboembolism: which Patients, which Cancers , 1997, Thrombosis and Haemostasis.

[81]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[82]  P. Prandoni,et al.  Venous thromboembolism and cancer: a two-way clinical association. , 1997, Frontiers in bioscience : a journal and virtual library.

[83]  E. Cook,et al.  Importance of Findings on the Initial Evaluation for Cancer in Patients with Symptomatic Idiopathic Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[84]  J. Hirsh,et al.  Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer , 1994, The Lancet.

[85]  T. Kjellstrom,et al.  Deep venous thrombosis and occult malignancy: an epidemiological study , 1994, BMJ.

[86]  P A Dekker-de Kiefte,et al.  Diagnosis and Treatment , 2020, Diabetes.

[87]  A. Carpi,et al.  Plasmatic parameters of fibrin formation and degradation in cancer patients: correlation between fibrinopeptide A and D-dimer. , 1993, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[88]  R. Scorza,et al.  Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders , 1993, British journal of haematology.

[89]  M. Monreal,et al.  Occult cancer in patients with acute pulmonary embolism. A prospective study. , 1993, Chest.

[90]  T S Edgington,et al.  Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[91]  M. Prins,et al.  Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. , 1992, The New England journal of medicine.

[92]  Venous thromboembolism and cancer. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[93]  S. Gordon,et al.  An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. , 1990, Cancer research.

[94]  P. Benotti,et al.  Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.

[95]  J. Gore,et al.  Occult cancer in patients with acute pulmonary embolism. , 1982, Annals of internal medicine.

[96]  I. Magrath,et al.  Acute tumor lysis syndrome: A review of 37 patients with Burkitt's lymphoma , 1980 .

[97]  W. Beattie,et al.  Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf , 1977, Neurology.

[98]  C. Warlow,et al.  Deep venous thrombosis of the legs after strokes. Part I--incidence and predisposing factors. , 1976, British medical journal.

[99]  N. Gibbs,et al.  Venous thrombosis of the lower limbs with particular reference to bed‐rest , 1957, The British journal of surgery.